Opexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company. The Company is engaged in developing personalized cellular therapies with the potential to treat illnesses, including multiple sclerosis (MS). These therapies are based on its T-cell technology. The Company�s core product candidate, Tovaxin, is a personalized T-cell therapeutic vaccine licensed from Baylor College of Medicine, which is in clinical development for the treatment of MS. Tovaxin is a T-cell immunotherapy positioned to enter Phase III clinical development for the treatment of relapsing remitting MS (RR-MS). In November 2011, the Company re-acquired the stem cell assets from Novartis Pharmaceuticals. Tovaxin is a personalized therapy that is specifically tailored to each patient�s disease profile. Tovaxin is manufactured using its method for the production of a patient-specific T-cell immunotherapy.